New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis

Nephrology Dialysis Transplantation

Volumn 30, Issue 11, 2015, Pages 1842-1852

  Glorieux, Griet ^a   Mullen, William ^b   Duranton, Flore ^c   Filip, Szymon ^d,e   Gayrard, Nathalie ^c   Husi, Holger ^b   Schepers, Eva ^a   Neirynck, Nathalie ^a   Schanstra, Joost P ^f,g   Jankowski, Joachim ^h   Mischak, Harald ^b,i   Argilés, Àngel ^c   Vanholder, Raymond ^a   Vlahou, Antonia ^d,j   Klein, Julie ^f,g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c RD Nephrologie   (France)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f INSERM   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁱ Mosaiques Diagnostics   (Germany)

^j PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

more..

Author keywords

Biomarkers; Chronic kidney disease; Haemodialysis; Mechanisms; Proteomics; Uraemic solutes

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT FACTOR D; CYSTATIN C; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; LYSOZYME; LYSOZYME C; PROSTAGLANDIN D SYNTHASE; PROTEOME; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ANALYSIS; VALIDATION STUDY; BLOOD; CHRONIC KIDNEY FAILURE; PROCEDURES; TANDEM MASS SPECTROMETRY;

AGED; BIOMARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOME; RENAL INSUFFICIENCY, CHRONIC; TANDEM MASS SPECTROMETRY;

EID: 84948418338     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv254     Document Type: Article

References (51)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
3. Dalrymple LS, Katz R, KestenbaumB et al. Chronic kidneydisease andthe risk of end-stage renal disease versus death. J Gen Intern Med 2011; 26: 379-385
4. Moody WE, Edwards NC, Chue CD et al. Arterial disease in chronic kidney disease. Heart 2013; 99: 365-372
5. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081
6. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
7. Bansal S, Siddarth M, Chawla D et al. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol Cell Biochem 2012; 361: 289-296
8. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-592
9. Nguyen-Khoa T, Massy ZA, De Bandt JP et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-340
10. Afsar B, Turkmen K, Covic A et al. An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014; 2014: 767424
11. Duranton F, Cohen G, De Smet R et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258-1270
12. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
13. Liabeuf S, Lenglet A, Desjardins L et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012; 82: 1297-1303
14. Lin Z, Zhou Z, Liu Y et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011; 6: e18398
15. Malickova K, Brodska H, Lachmanova J et al. Plasma calprotectin in chronically dialyzed end-stage renal disease patients. Inflamm Res 2010; 59: 299-305
16. Sabbisetti VS,Waikar SS, Antoine DJ et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 2014; 25: 2177-2186
17. Celap I, SimundicAM, NikolacNet al. Visfatin is not associated with inflammatory markers in patients on hemodialysis. Clin Lab 2013; 59: 1253-1259
18. Yilmaz MI, Siriopol D, SaglamMet al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213-1220
19. Husi H, Sanchez-Nino MD, Delles C et al. A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol 2013; 7: 110
20. Husi H, Van Agtmael T, Mullen Wet al. Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet 2014; 7: 161-170
21. Haab BB, Geierstanger BH, Michailidis G et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005; 5: 3278-3291
22. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008; 54: 1608-1616
23. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1: 1-48
24. Andersen RF, Palmfeldt J, Jespersen B et al. Plasma and urine proteomic profiles in childhood idiopathic nephrotic syndrome. Proteomics Clin Appl 2012; 6: 382-393
25. Majek P, Riedelova-Reicheltova Z, Suttnar J et al. Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. Dis Markers 2014; 2014: 178709
26. Xu DD, Deng DF, Li X et al. Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled twodimensional LC-MS/MS. Proteomics 2014; 14: 322-331
27. Gotes J, Kasian K, JacobsHet al. Lysozyme, a mediator of sepsis that deposits in the systemic vasculature and kidney as a possible mechanism of acute organ dysfunction. Shock 2014; 41: 256-265
28. Mink SN, Kasian K, Santos Martinez LE et al. Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation. Am J Physiol Heart Circ Physiol 2008; 294: H1724-H1735
29. Watson CJ, Ledwidge MT, Phelan D et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail 2011; 4: 188-197
30. Linden M, Lind SB, Mayrhofer C et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 2012; 12: 135-144
31. Wen SY, Zhang LN, Yang XM et al. LRG1 is an independent prognostic factor for endometrial carcinoma. Tumour Biol 2014; 35: 7125-7133
32. He X, Wang Y, Zhang Wet al. Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ-MALDI-MS/MS. Neoplasma 2014; 61: 17-26
33. Kentsis A, Ahmed S, Kurek K et al. Detection and diagnostic value of urine leucine-rich alpha-2-glycoprotein in children with suspected acute appendicitis. Ann Emerg Med 2012; 60: 78-83 e71
34. Serada S, Fujimoto M, Terabe F et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 2012; 18: 2169-2179
35. Wang X, Abraham S, McKenzie JA et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 2013; 499: 306-311
36. Michel JB, Martin-Ventura JL, Nicoletti A et al. Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014; 234: 311-319
37. Kalantari S, Rutishauser D, Samavat S et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS One 2013; 8: e80830
38. Vivekanandan-Giri A, Slocum JL, Buller CL et al. Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics 2011; 2011: 214715
39. Abdul-Salam VB, Ramrakha P, Krishnan U et al. Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1027-1033
40. Romao JE, Jr, Haiashi AR, Elias RM et al. Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol 2006; 26: 59-66
41. Schoorl M, Grooteman MP, Bartels PC et al. Aspects of platelet disturbances in haemodialysis patients. Clin Kidney J 2013; 6: 266-271
42. Volanakis JE, Barnum SR, Giddens Met al. Renal filtration and catabolism of complement protein D. N Engl J Med 1985; 312: 395-399
43. Beazley KE, Reckard S, Nurminsky D et al. Two sides of MGP null arterial disease: chondrogenic lesions dependent on transglutaminase 2 and elastin fragmentation associated with induction of adipsin. J Biol Chem 2013; 288: 31400-31408
44. Zhu L,Wigle D, Hinek A et al. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest 1994; 94: 1163-1171
45. Adams MJ, Irish AB,Watts GF et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008; 123: 374-380
46. Matsuo T, Koide M, Kario K et al. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 1997; 27: 163-167
47. Sioulis A, Malindretos P, Makedou A et al. Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients. Hippokratia 2009; 13: 237-241
48. Tan CC, Lee GS, Lee EJ et al. Plasma activity of contact coagulation factors in patients with IgA nephritis. Ann Acad Med Singapore 1996; 25: 218-221
49. Deguchi K, Izumi K, Noguchi M et al. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis. Nihon Ketsueki Gakkai Zasshi 1989; 52: 140-146
50. Oda H, Ohno M, Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial 2000; 16: 152-155
51. Papageorgiou PC, Chan CT, Yeo EL et al. Coagulation Factor XIIa-kininmediated contribution to hypertension of chronic kidney disease. J Hypertens 2014; 32: 1523-1533; discussion 1533